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Volume 52, Number 3 Abstracts 7992% to 6% of patients with a hemodynamically stable PE and in 30% of
patients with PE presenting with shock or hemodynamic instability (Chest
2002;121:877-905; Arch Intern Med 2004;164:92-96). About 25% of
patients do not survive the first year after the diagnosis of PE, with most
deaths relating to cancer or chronic heart disease rather than to PE itself
(N Engl J Med 1992; 326:1240-1245). We also know that patients with PE
are at risk for recurrent PE, chronic thromboembolic pulmonary hyperten-
sion, arterial cardiovascular events, and a new diagnosis of cancer (N Engl
J Med 1998;338:1169-73; AMA 2005;293:2352-61). The goal of this
study was to assess long-term risk for adverse events after PE.
The authors analyzed consecutive patients diagnosed with PE between
January 2001 and July 2007. Patients were monitored until July 2008 for
occurrence of adverse clinical events, defined as death, symptomatic or
recurrent venous thromboembolism, cancer, arterial cardiovascular events,
and chronic thromboembolic pulmonary hypertension. Statistical analysis
included calculation of hazard ratios (HR) and 95% confidence intervals (CI)
for individual end points and a combined end point with adjustments for
confounders. There were 308 patients with unprovoked and 558 patients
with provoked PE. An additional 334 patients without PE were also studied.
Median follow-up was 3.3 years. Patients with unprovoked PE had a lower
overall risk for death than patients with provoked PE (HR, 0.59; 95% CI,
0.43-0.82). However, they had a higher risk for non-malignancy-related
death (HR, 1.8; 95% CI, 1.3-2.5), recurrent venous thromboembolism
(HR, 2.1; 95% CI, 1.3-3.1), cancer (HR, 4.4; 95% CI, 2.0-10), cardiovas-
cular events (HR, 2.6; 95% CI, 1.5-3.8), and chronic thromboembolic
pulmonary hypertension (1.5% vs 0%). The fraction of patients with pro-
voked and unprovoked PE without events after 1 year was 70%, decreased to
60% after 2 years, and was 50% after 4 years. In comparison, 85% of
patients without PE were free of clinical events after 4 years.
Comment: These data are sobering. More than 70% of patients with
PE will have had a major clinical event by 4 years after the PE. One is
tempted to ascribe the late events to the initial occurrence of the PE, but
clearly, a diagnosis of cancer as a late clinical event is not caused by the PE.
Nevertheless, the high rate of late adverse events that are potentially related
to the initial PE (recurrent PE, recurrent venous thromboembolism, and
thromboembolic pulmonary hypertension) argues for better protocols for
prevention of PE through individual risk stratification of at-risk patients.
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Engl J Med 2010;363:11-23.Conclusion: In patients with symptomatic or asymptomatic carotid
stenosis, a composite outcome of stroke, myocardial infarction, or deathdoes not differ between patients undergoing endarterectomy or those
undergoing carotid artery stenting. During the periprocedural period, there
is a higher risk of stroke with stenting and a higher risk of myocardial
infarction with endarterectomy.
Summary: The authors randomly assigned patients with asymptomatic
or symptomatic carotid artery stenosis to undergo carotid endarterectomy or
carotid artery stenting. The primary end point was a composite end point of
stroke, myocardial infarction, or death from any cause during the peripro-
cedural period or any ipsilateral stroke 4 years after randomization. There
were 2502 patients participating in the study, with a median follow-up of 2.5
years. There were no significant differences in the estimated 4-year rates of
the primary end point between the stenting group and the endarterectomy
group (7.2% and 6.8%, respectively; hazard ratio with stenting, 1.11; 95%
confidence interval, 0.81-1.51; P  .51). The primary end point did not
differ according to sex (P .34) or symptomatic status (P .84). The 4-year
rate of stroke or death was 6.4% with stenting and 4.7% with endarterectomy
(hazard ratio, 1.37; P .14). Rates among asymptomatic patients were 4.5%
and 2.7%, respectively (hazard ratio, 1.86; P  .07). There were differences
in periprocedural rates of individual components of the end points between
the stenting and endarterectomy group. Rates of death for stenting were
0.7% vs 0.3% for endarterectomy (P  .18). Rates of stroke were 4.1% for
stenting vs 2.3% for endarterectomy (P  .01). Rates of myocardial infarc-
tion were 1.1% for stenting vs 2.3% for endarterectomy (P .03). After the
periprocedural period, incidences of ipsilateral stroke with stenting and with
endarterectomy were both low (2% vs 2.4%, respectively; P  .85).
Comment:The CREST results are finally published. The question now
is what do we do with them? The primary end point of the study, a
combination of stroke, death, and myocardial infarction, did not differ
between the stented and surgically treated patients (P  .38). This was
secondary to a higher incidence of periprocedural myocardial infarction in
the endarterectomy patients. Rates of stroke and death were higher in the
stented group, both in the periprocedural period and out to 4 years (any
stroke, P .01; any periprocedural or postprocedural ipsilateral stroke, P
.01; any periprocedural stroke or death or postprocedural ipsilateral stroke;
P .0.005; Table 2 of the article). The results basically mirror those of other
government-sponsored large randomized trials that favored endarterectomy
over stenting for stroke prevention or failed to establish noninferiority of
stenting (Ederle J, et al [Lancet 2010;375:985-97]; Mas J-L, et al [N Engl
J Med 2006;355:1660-71]; and Ringleb PA, et al [Lancet 2006;368:1239-
47]) Additional analysis in CREST indicated stroke had an adverse long-
term outcome on quality of life, whereas perioperative myocardial infarction
had no effect on quality of life measures. Overall it would seem the evidence
favors endarterectomy over stenting, but this will surely continue to be
debated.
